98510-20-4

Usage

Uses

Used in Pharmaceutical Industry:
1,3,5-O-METHYLIDYNE-MYO-INOSITOL is used as a key intermediate in the synthesis of myo-inositol phosphates for their potential applications in the development of pharmaceuticals targeting various diseases and conditions.
Used in Research and Development:
1,3,5-O-METHYLIDYNE-MYO-INOSITOL is utilized as a valuable compound in research and development for studying the role of myo-inositol phosphates in cellular signaling, membrane trafficking, and other biological functions.

InChI:InChI=1/C7H10O6/c8-1-4-2(9)6-3(10)5(1)12-7(11-4)13-6/h1-10H

Upstream product

• 87-89-8 D-myo-inositol 
• 122-51-0 orthoformic acid triethyl ester 
• 67-68-5 dimethyl sulfoxide 
• 488-59-5 myo-inositol 
• 98510-21-5 2,4,6-tri-O-acetyl-myo-inositol 1,3,5-orthoformate 
• 149-73-5 trimethyl orthoformate 

Downstream Products

• 145124-81-8 1L-2-O-acetyl-1,3,5-O-methylidyne-4-O-(2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl)-myo-inositol 
• 145124-81-8 1D-2-O-acetyl-1,3,5-O-methylidyne-4-O-(2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl)-myo-inositol 
• 114847-11-9 meso-2,4,6-tri-O-benzyl-D-myo-inositol-1,3,5-O-orthoformate 
• 98510-25-9 meso-4,6-di-O-benzyl-D-myo-inositol-1,3,5-O-orthoformate 
• 98510-25-9 racemic 2,4-di-O-benzyl-myo-inositol 1,3,5-orthoformate 
• 120268-33-9 4/6-O-benzyl-myo-inositol 1,3,5-monoorthoformate 
• 114828-08-9 2,4,6-tri-O-benzyl-myo-inositol 
• 153325-42-9 4,6-di-O-benzoyl-myo-inositol 
• 162062-52-4 1,3-di-O-benzoyl-myo-inositol 
• 198486-36-1 C₄₁H₃₈O₈ 
• 4922-14-9 Hexaoxadiamantan 
• 98510-27-1 (1S,5S,7R,8S,9R)-8,9-Bis-benzyloxy-2,4,10-trioxa-tricyclo[3.3.1.1^3,7]decan-6-one 
• 98510-24-8 (1R,3S,5S,6R,7S,8S,9S)-6,8-bis(benzyloxy)-9-<(tert-butyl)dimethylsilyloxy>-2,4,10-tri-oxatricyclo<3.3.1.1^3,7>decane 
• 98575-46-3 (1R,5R,6S,7S,8R,9S)-8,9-Bis-benzyloxy-2,4,10-trioxa-tricyclo[3.3.1.1^3,7]decan-6-ol 

Relevant academic research and scientific papers

myo-inositol 4,6-carbonate: An easily prepared small molecule with three syn-axial hydroxyl groups

myo-Inositol 4,6-carbonate, a compound having three syn-axial hydroxyl groups, was synthesized in four steps suitable for gram-scale preparation. It readily forms complexes with cations.

Formation of (±)-1,2-O-ethylidene-myo-inositol during the reaction between triethyl orthoformate and myo-inositol in DMSO

Besides myo-inositol monoorthoformate (1), (±)-1,2-O-ethylidene-myo-inositol (2) was obtained as another product in the reaction between triethyl orthoformate and myo-inositol in DMSO catalyzed by acid under N2.

First synthesis of 3-O-methyl-scyllo-inosamine, a natural product which favors the Rhizobium-Leguminosae symbiosis

Rhizopine, extracted in small amounts from nodules induced by Sinorhizobium meliloti strain L5-30 infection of alfalfa, was proved to possess the 3-O-methyl-scyllo-inosamine gross structure.

Silver (I) oxide assisted O-alkylation of 2,4-di-O-benzoyl-myo-inositol-1,3,5-orthoformate and its 6-O-substituted derivatives: Transannular participation of oxygen

The reaction of 2,4-di-O-benzoyl-myo-inositol-1,3,5-orthoformate and its 6-O-substituted derivatives with alkyl halides in the presence of silver (I) oxide has been studied systematically. The nature of the product obtained depends on the amount of silver (I) oxide and alkyl halides used as well as on the solvent employed for the reaction. By varying these parameters, the corresponding symmetrical 4,6-di-O-alkylated or 4-mono-O-alkylated myo-inositol-1,3,5-orthoformates can be obtained in good yields. These alkylations proceed by two different pathways which involve the transannular participation of the neighbouring oxygen. Results presented for the allylation of 2,4-di-O-benzoyl-myo-inositol-1,3,5-orthoformate suggest cleavage and allylation of the axial 4-benzoate moiety prior to allylation of the free C-6-hydroxyl group. Involvement of a myo-inositol orthoformate-silver complex during these alkylation reactions is suggested.

2-O-Benzoyl-myo-inositol-1,3,5-orthoformate

Protected myo-inositol derivatives are important precursors in the synthesis of phosphorylated myo-inositol derivatives, which play a significant role in cellular signal transduction. The structure of the title compound, C14H14O

Exciplex and excimer molecular probes: Detection of conformational flip in a myo-inositol chair

2-O-tert-Butyldimethylsilyl-4,6-bis-O-pyrenoyl-myo-inositol-1,3, 5-orthoformate (6) and 2-O-tert-butyldimethylsilyl-4-O-[4-(dimethylamino) benzoyl]-6-O-pyrenoyl-myo-inositol-1,3,5-orthoacetate (10) adopt conformationally restricted unstable chairs with fi

ACETYLATED PRODRUGS FOR DELIVERY ACROSS THE BLOOD-BRAIN BARRIER

The present disclosure relates to pharmaceutical compositions including a compound derived from a parent compound having a hydroxyl or amino moiety, wherein the hydroxyl in the parent compound is presented as an ester in the compound or the amino in the parent compound is presented as an amide in the compound, and their use to prevent or treat neurological disease.

Lithium hydride as an efficient reagent for the preparation of 1,2-anhydro inositols: Does the reaction proceed through ‘axial rich’ conformation?

scyllo-Inositol derived 1,2-trans-diequatorial halohydrins can be efficiently converted to the corresponding epoxides in the presence of lithium hydride. The structure of one of the epoxides was determined by single crystal X-ray diffraction analysis. Thi

4,6-DI-(O-THIOPHOSPHATE)-INOSITOL-1,2,3,5-TETRA-O-SULFATE FOR C. DIFFICILE INFECTION

The present invention relates to inositol bisthiophosphates-tetrakissulfates, particularly for use in treating symptoms associated with Clostridium difficile infection.

INOSITOL DERIVATIVES FOR USE IN PATHOLOGICAL CRYSTALLIZATION

The present invention relates to inositol derivatives covalently modified with one, two or three solubility functions, particularly polyethylene glycol moieties, for use in therapy or prevention of conditions related to pathological calcium crystallizatio